February 7, 2014 by Brad Perriello
The U.S. Patent & Trademark Office nixes 2 patents at issue in Smith & Nephew's long-running infringement battle with Interlace Medical and subsequent acquirer Hologic. The U.S. Patent & Trademark Office dealt a setback to Smith & Nephew (FTSE: SN , NYSE: SNN ) last month when it invalidated claims in a pair of patents at the core of a long-running infringement dispute with Interlace Medical and its subsequent acquirer, Hologic  (NSDQ: HOLX ). Smith & Nephew sued Interlace in 2010, alleging infringement of a pair of patents with the MyoSure fibroid tumor device, and filed against Hologic after the Interlace buyout in January 2011. Sign up to get our free newsletters delivered right to your inbox. In September 2012, a jury  awarded $4 million in damages  to cover Smith & Nephew's lost profits from the infringement. Further damages, however, can't yet be decided because the jury's verdict was too vague, according to Judge Rya Zobel of the U.S. District Court for Massachusetts. In October 2013, Hologic  asked a federal judge in Massachusetts to revisit that loss . Last June, Judge Rya Zobel of the U.S. District Court for Massachusetts  upheld that decision  but found that any damages owed by Hologic to the British medical products giant couldn't yet be determined.

U.S. Patent Office nixes Smith & Nephew patents in spat with Hologic

Membrane oxygenation on the rise and ready for disruption in Germany
The number of extracorporeal membrane oxygenation (ECMO) procedures in Germany rose to 5,949 in 2014 effectively tripling the number of procedures in five years, reports consultancy firm, assets Consulting Healthcare GmbH. The report is based on observation of OPS codes in Germany that were recently released by the German Institute of Medical Documentation and Information (DIMDI). […]
Real drug or counterfeit? TruTag Technologies reader & edible barcode can tell
TruTag Technologies Inc. had developed an innovative, edible product security solution that addresses the trillion-dollar global counterfeit problem. At a recent event, TruTag Director of Business Development Steven Yoder presented on the latest advancements in security features for food and drug packaging entitled:  “Going Beyond the Package:  What’s Next in Food and Pharmaceutical Security.” TruTag Technologies […]
BeVITAL app connects post-surgical patients and physicians
Wearable biosensor firm Vital Connect, Inc. and start up BePATIENT have released a new system called BeVITAL. The remote patient monitoring solution combines VitalConnect’s FDA-cleared biosensor, HealthPatch MD, with BePATIENT’s web-based solution and associated app, to enable personalized healthcare programs accessible through mobile devices and computers. BeVITAL is designed for patients after they’ve been discharged […]
Collaboration speeds Waters Corp. through new product introduction, brings innovative mass detector to life
In 2013, analytical-instrument manufacturer Waters Corporation set out to develop a cost-effective mass detector that met specific size, usability, and affordability requirements. The detector required an agile development organization and a particular time-to-market window while meeting high quality standards. The detector, called ACQUITY QDa, came from a technically complex project because Waters engineers planned to […]
Rowiak looks to use lasers to treat presbyopia at its source with ‘seeing scalpel’
Rowiak Co. is looking to treat nearsightedness – also known as presbyopia – using a femtosecond laser and optical coherence tomography. Called the “seeing scalpel,” the technology is designed to be customized for treating difference ophthalmological disorders, the company said. Hannover, Germany-based Rowiak spun out of the Laser Zentrum Hannover in 2003. “As experts in […]
Hamilton Thorne’s 2015 profits jump 20%
Profits for Hamilton Thorne (CVE:HTL) jumped 20% last year as the laser maker’s focus on its core markets paid off. The Beverly, Mass., and Toronto-based company, which makes precision laser devices and image analysis systems for the assisted reproductive technologies, regenerative medicine and developmental biology research markets, posted profits of $1.0 million, or 2¢ per […]
CS Medical releases QuikDry TEE probe drying cloth
CREEDMOOR, NORTH CAROLINA – CS Medical announces the release of their newest product designed to aid in the circle of care for TEE probes. The QwikDry TEE Ultrasound Probe Drying Cloth is designed to effectively dry TEE ultrasound probes at the conclusion of high-level disinfection and rinse. The TEE ultrasound probes should be thoroughly dried […]
Atlas Vac Machine offers All Electric medical device tray sealer
Atlas Vac Machine’s lineup of tray sealers now includes an All Electric Sealer — no pneumatics. In seeking the ultimate in precise down-force control, our engineers have replaced the traditional pneumatic press with the next generation of press drive systems. Coupled with the heaviest heater & platen cross section in the industry, electric auto shuttles, […]
UV Disinfection continues to grow in infection control
Ultraviolet Light Disinfection is not a new technology to many industries, but more and more experts are utilizing the technology in the growing concern of providing infection control in hospitals globally. The most recent area of the world to take an interest in using UV in these capacities is Canada. UV disinfection works by utilizing […]
SL Power’s new MU425S AC/DC power supply family improves medical equipment power performance
SL Power Electronics, a division of SL Industries and an industry leader in the design and manufacture of rugged, highly reliable power supplies, today announces its 425 watt, single output MU425 Series AC/DC power supply. This latest offering addresses the complexity and unique power needs of healthcare systems such as surgical equipment, home healthcare therapeutic […]
Newport introduces 2-inch, vertical drive mirror mount for industrial application
Newport Corporation, a worldwide leader in photonic solutions, expands its industry leading portfolio of opto-mechanics with the HVM-2i, a compact and robust vertical drive kinematic mount for 2 inch diameter optics. The HVM-2i features a unique ball-and-wedge drive mechanism that enhances the overall performance of the optical mount by reducing stiction and backlash to negligible […]
Leave a Reply
You must be logged in to post a comment. Need Medtech news in a minute? We Deliver! MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today. Tweets by @MassDevice
Need Medtech news in a minute? We Deliver! MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today. Medical Design & Outsourcing covers the technical advancements in design, development, and contract manufacturing of medical devices and equipment. DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights. Follow us

Hologic asks court to revisit loss to Smith & Nephew over MyoSure device

Hologic says a Massachusetts jury ruled against it in a patent infringement lawsuit, awarding damages of $4 million over the MyoSure device Hologic acquired along with Interlace Medical.
        
        


Legal News, News Well, Patent Infringement, Women&amp;#039;s Healthread more

Hologic loses $4M patent suit to Smith &amp; Nephew over Interlace fibroid tech

Hologic Buys Interlace Medical for $125 Mln
January 11, 2011
Follow @luisarbeltran
Interlace Medical, which was backed by Baird Venture Partners, has been sold to Hologic for $125 million. Additional earn-out payments can take place over the next two years, a statement said. Framingham, Mass.-based Interlace is a medical device company that has developed the MyoSure, which is used to remove intrauterine fibroids and polyps. Interlace received $20.5 million in Series C financing in 2009 from investors including BVP, Spray Venture Partners and New Leaf Venture Partners. Baird Venture Partners is the U.S. VC fund of Baird Private Equity. PRESS RELEASE
Baird Venture Partners (BVP), the U.S.-based venture fund of Baird Private Equity, announced today that Interlace Medical (Interlace), a Baird Venture Partners III portfolio company, has been sold to Hologic for $125 million with additional earn-out payments over the next two years. This acquisition will allow Interlace to accelerate the adoption of its products through the Hologic distribution network. In June 2009, Interlace raised $20.5 million in Series C financing from investors that included BVP, Spray Venture Partners, New Leaf Venture Partners, HLM Venture Partners, Hambrecht & Quist Capital Management LLC, and Aperture Venture Partners. Based in Framingham, Mass., Interlace is a medical device company dedicated to providing novel solutions within the women’s health sector. Interlace developed and commercialized the MyoSure™ system, an easy-to-use, minimally invasive treatment to remove intrauterine fibroids and polyps. Fibroids are a common cause of abnormal uterine bleeding, which afflicts 5 million women in the United States. The MyoSure system’s allows physicians the flexibility to conduct procedures in either an operating room or office setting. “We were able to partner with a great management team at Interlace to develop a much needed product serving the women’s health sector,” said Michael Liang, BVP Partner. “The acquisition of Interlace by Hologic provides a nice early return for our BVP III investors, and further validates our strategy of proactively identifying healthcare companies that are capital efficient and can be an attractive acquisition for trade buyers.”
“Baird Venture Partners has been a great partner for us,” said Bill Gruber, Interlace President and CEO. “Their lead role in our latest financing and active role on the Board accelerated our growth initiatives and ability to get the MyoSure product into the marketplace. Their involvement was invaluable to help us enter our next phase of growth as part of Hologic.”
Baird Venture Partners raised BVP III, a $170 million fund, in 2008. The Fund has made eight investments to date. About Baird Venture Partners
Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early and expansion stage business services and life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. For more information, please visit www.bairdventurepartners.com. About Baird Private Equity
Baird Private Equity, the global private equity group of Robert W. Baird & Co. (Baird), makes venture capital, growth equity and buyout investments in smaller, high potential companies in the United States through Baird Venture Partners and Baird Capital Partners, in China through Baird Capital Partners Asia, and in Europe through Baird Capital Partners Europe. Baird Private Equity has a global team of investment and operations professionals in nine offices across the United States, Europe and Asia, including a team of operating professionals in Asia. Baird Private Equity and its affiliates have raised and managed over $2.7 billion in capital and invested in more than 240 companies since the 1980s. For more information, please visit www.bairdprivateequity.com. © 2015 Buyouts Insider / Argosy Group LLC

Hologic Buys Interlace Medical for $125 Mln

XconomyBoston — 
Bedford, MA-based Hologic, a provider of diagnostics, medical imaging, and surgical products for women, announced today that it has bought Interlace Medical of Framingham, MA, for $125 million in cash. Interlace, which makes a hysteroscopic tissue removal system, will be integrated into Hologic’s (NASDAQ: HOLX ) gynecological surgical products business. The deal also includes two annual contingent payments, which will be a “multiple of the incremental revenue growth over the prior year,” according to the announcement.

Hologic Buys Interlace for $125M

Interlace Medical

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

Interlace Medical Corporation designs and develops minimally invasive devices for the gynecological surgeon to aid them in removal of uterine fibroids and polyps.

Hologic

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip, an investigational device in the US
October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. Data include findings from the  TRILUMINATE  pivotal trial that reinforce the safety and effectiveness of the TriClip transcatheter edge-to-edge repair (TEER) system for patients with symptomatic, severe tricuspid regurgitation (TR) despite optimal medical therapy. The company also presented late-breaking data from the  MitraClip EXPAND G4  real-world registry that highlights the device's benefits across a broad group of patients with mitral regurgitation (MR). Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should. As a result, MR and TR can lead to other cardiovascular issues as well as severely limit a person's quality of life. While historically surgery was often necessary to combat MR and TR, Abbott's minimally invasive portfolio of structural heart devices has allowed more people around the world to be effectively treated without the risk of surgical complications. The following studies using products from Abbott's industry-leading structural heart portfolio were presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in San Francisco (October 23-26, 2023). TriClip: New TRILUMINATE Pivotal Trial Data
The  TRILUMINATE pivotal trial  is the world's first randomized, controlled clinical study evaluating the safety and effectiveness of transcatheter repair with the TriClip system compared to medical therapy in people with severe TR. Outcomes to date for all randomized patients (N=572) and those enrolled in the concurrent single-arm group (patients with more complex tricuspid valve anatomy) were presented for the first time at TCT and illustrated the device's safety, effectiveness and benefits. Key findings from the TRILUMINATE pivotal trial through one year include:
Consistent with and reinforcing the findings in the primary randomized population (N=350, presented at ACC 2023), TriClip therapy demonstrated significant improvements in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of social abilities, symptoms and quality of life) for the full randomized group, along with an excellent safety profile. The single-arm group with more complex anatomies and advanced disease met its primary endpoint. The data demonstrated that TriClip was safe, with 81% of patients achieving TR reduction to moderate or less and reporting a similar degree of KCCQ improvement to the randomized population. "The updated TRILUMINATE pivotal results confirm what has previously been shown – that TriClip is safe and effective for patients with severe tricuspid regurgitation," said  David Adams , M.D., chairman of the department of cardiovascular surgery at the Icahn School of Medicine at Mount Sinai and cardiac surgeon-in-chief of the Mount Sinai Health System, who served as co-primary investigator of the trial. "With the addition of the single-arm data that include people with more complex tricuspid anatomies, the takeaway is that TriClip is reducing TR effectively and patients are subsequently experiencing improvement in their quality of life." MitraClip: One-Year Results From the EXPAND G4 Study
The  EXPAND G4 study  is a prospective, multi-center, global, real-world study of more than 1,100 patients that reinforces the safety and effectiveness of the MitraClip G4 system in people with a broad range of anatomies. One-year results were simultaneously published in  JACC: Cardiovascular Interventions . Key findings from the EXPAND G4 study at one year include:
The highest reported MR reduction in a mitral TEER study to date, sustained through one year, with MR reduction to mild or less (≤ grade 1+ on a five-point scale) achieved in 93% of patients, and trace or less MR achieved in 44% of patients. Significant clinical improvements, including 82% of patients achieving New York Heart Association (NYHA) Functional Class I/II (meaning they reached a point of slight or no limitation of physical activity), an improvement from 36% at baseline; and a 19-point improvement in KCCQ score. MitraClip showed the lowest rates of all-cause mortality (12%) and hospitalization for heart failure (17%) in a global, real-world mitral TEER study. "These late-breaking data at TCT offer further evidence that our innovative, minimally-invasive heart devices are having a positive impact on the lives and well-being of those with structural heart disease," said  Michael Dale , senior vice president of Abbott's structural heart business. "For more than two decades, Abbott has continued to evolve and expand its minimally invasive treatment options for mitral and tricuspid regurgitation. Our portfolio of technologies to restore health and improve the quality of life of patients with leaky valves represents new standards of care and an example of our commitment to leadership in the treatment of structural heart disease." For more information:  https://abbo.tt/MitraClipISI .

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

News provided by
Share this article
Share toX
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S. One-year outcomes from the EXPAND G4 study, simultaneously published in JACC: Cardiovascular Interventions, reinforce durable safety and effectiveness of MitraClip™ with significant mitral regurgitation reduction
ABBOTT PARK, Ill., Oct. 24, 2023 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. Data include findings from the TRILUMINATE™ pivotal trial that reinforce the safety and effectiveness of the TriClip™ transcatheter edge-to-edge repair (TEER) system for patients with symptomatic, severe tricuspid regurgitation (TR) despite optimal medical therapy. The company also presented late-breaking data from the MitraClip™ EXPAND G4 real-world registry that highlights the device's benefits across a broad group of patients with mitral regurgitation (MR). Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should. As a result, MR and TR can lead to other cardiovascular issues as well as severely limit a person's quality of life. While historically surgery was often necessary to combat MR and TR, Abbott's minimally invasive portfolio of structural heart devices has allowed more people around the world to be effectively treated without the risk of surgical complications. The following studies using products from Abbott's industry-leading structural heart portfolio were presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in San Francisco (October 23-26, 2023). TriClip: New TRILUMINATE Pivotal Trial Data
The TRILUMINATE pivotal trial is the world's first randomized, controlled clinical study evaluating the safety and effectiveness of transcatheter repair with the TriClip system compared to medical therapy in people with severe TR. Outcomes to date for all randomized patients (N=572) and those enrolled in the concurrent single-arm group (patients with more complex tricuspid valve anatomy) were presented for the first time at TCT and illustrated the device's safety, effectiveness and benefits. Key findings from the TRILUMINATE pivotal trial through one year include:
Consistent with and reinforcing the findings in the primary randomized population (N=350, presented at ACC 2023), TriClip therapy demonstrated significant improvements in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of social abilities, symptoms and quality of life) for the full randomized group, along with an excellent safety profile. The single-arm group with more complex anatomies and advanced disease met its primary endpoint. The data demonstrated that TriClip was safe, with 81% of patients achieving TR reduction to moderate or less and reporting a similar degree of KCCQ improvement to the randomized population. "The updated TRILUMINATE pivotal results confirm what has previously been shown – that TriClip is safe and effective for patients with severe tricuspid regurgitation," said David Adams, M.D., chairman of the department of cardiovascular surgery at the Icahn School of Medicine at Mount Sinai and cardiac surgeon-in-chief of the Mount Sinai Health System, who served as co-primary investigator of the trial. "With the addition of the single-arm data that include people with more complex tricuspid anatomies, the takeaway is that TriClip is reducing TR effectively and patients are subsequently experiencing improvement in their quality of life." MitraClip: One-Year Results From the EXPAND G4 Study
The EXPAND G4 study is a prospective, multi-center, global, real-world study of more than 1,100 patients that reinforces the safety and effectiveness of the MitraClip G4 system in people with a broad range of anatomies. One-year results were simultaneously published in JACC: Cardiovascular Interventions . Key findings from the EXPAND G4 study at one year include:
The highest reported MR reduction in a mitral TEER study to date, sustained through one year, with MR reduction to mild or less (≤ grade 1+ on a five-point scale) achieved in 93% of patients, and trace or less MR achieved in 44% of patients. Significant clinical improvements, including 82% of patients achieving New York Heart Association (NYHA) Functional Class I/II (meaning they reached a point of slight or no limitation of physical activity), an improvement from 36% at baseline; and a 19-point improvement in KCCQ score. MitraClip showed the lowest rates of all-cause mortality (12%) and hospitalization for heart failure (17%) in a global, real-world mitral TEER study. "These late-breaking data at TCT offer further evidence that our innovative, minimally-invasive heart devices are having a positive impact on the lives and well-being of those with structural heart disease," said Michael Dale, senior vice president of Abbott's structural heart business. "For more than two decades, Abbott has continued to evolve and expand its minimally invasive treatment options for mitral and tricuspid regurgitation. Our portfolio of technologies to restore health and improve the quality of life of patients with leaky valves represents new standards of care and an example of our commitment to leadership in the treatment of structural heart disease." For U.S. important safety information on MitraClip, visit  https://abbo.tt/MitraClipISI . TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the U.S.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at  www.abbott.com , on LinkedIn at  www.linkedin.com/company/abbott-/ , on Facebook at  www.facebook.com/Abbott  and on Twitter @AbbottNews. SOURCE Abbott

DUBLIN--(BUSINESS WIRE)--The "Pulse Oximeter Market Size, Share & Trends Analysis Report By Product Type (Fingertip pulse oximeters, Handheld pulse oximeters), By Type, By Age Group, By Technology, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering. The global pulse oximeter market size is expected to reach USD 3.9 billion by 2030, registering a CAGR of 6.4% from 2023 to 2030. The pulse oximeter industry is anticipated to wi

Global Pulse Oximeter Market Forecasts to 2030: Rising Demand for Minimally Invasive Devices Drives Growth - ResearchAndMarkets.com

Capsule Endoscopy Segment to Gain Higher Traction as a Result of High Success Rate of the Procedure
The capsule endoscopy technology segment is expected to see significant growth in the smart pills technology market over the next several years. Increased research activities drive this growth by various organizations, and positive results have been found in patients aged between 50 and 75. The latest research conducted by SkyQuest has revealed that capsule endoscopy provides better diagnostic results than CT colonography, which is expected to drive demand for this technology. The findings of this research are predicted to propel the growth of the capsule endoscopy segment over the forecast period, making it a key area of focus for market players. The smart pills technology market in North America is poised for strong growth over the forecast period, driven by medical researchers' advancements in the field of ingestible electronics. The region is at the forefront of major innovation in this field and has seen a significant investment and development activity increase. In addition, the growing support from regulators, such as the U.S. FDA, in the form of guidelines for securing approvals for digital smart pills is further fueling the market growth in this region. Browse summary of the report and Complete Table of Contents (ToC):
Hospital & Specialty Clinics Emerges as the Key End-User Segment owing to Increasing Patient Admissions
The end-user segment of hospitals and specialty clinics held a dominant share in the global smart pills technology market in 2022, accounting for nearly half of the total market share. A surge in colon cancer patients drives this segment's high demand for smart pills technology. On the other hand, the research centers segment is projected to expand fastest, with a CAGR of 12.6% during the forecast period. The strong growth in this segment is due to increased investments in research and development aimed at developing advanced smart pills technology. The regional market in the Asia Pacific is set for exponential progress in the coming years due to growing healthcare awareness. This region is expected to experience the fastest growth rate of 10.2% from 2023 to 2028, outpacing the global market. The technology of smart pills is still in its infancy in the Asian market. Still, the rise of corporate investments and favorable reimbursement policies, and increased funding for endoscopic research, are driving market expansion. As a result, companies operating in this region will be well-placed to take benefit of the rapidly growing demand for smart pills technology and capitalize on the lucrative market opportunities. SkyQuest's recent study sheds light on the latest developments and future prospects of the global smart pills technology market. The report provides a comprehensive market analysis by segmenting it based on various parameters such as target area, disease indication, application, and end user. The research also includes forecasting global, regional, and country-level markets from 2022 to 2028. Speak to Analyst for your custom requirements:
Key Developments in Smart Pills Technology Market
HealthBeacon plc, the innovative digital therapeutics company, has expanded its platform to better manage complicated and critical pill regimens by introducing its new HB Smart Pills Management System. This new offering follows the company's recent addition of the HB Smart Scale and its partnership with the American Pharmacists Association Foundation. The HB Smart Pills system is designed to make managing pill regimens easier and more efficient for patients and healthcare providers. AccelmedPartners, a prominent private equity firm in the health tech industry, recently announced its leading role in a USD 40 million investment in MedMinder Systems Inc. MedMinder is a cutting-edge company that provides a comprehensive and integrated solution for elderly and polypharmacy patients. This solution is designed to improve medication adherence and connected care, and it has quickly become the leading provider in this field. BD (Becton, Dickinson, and Company) and The Ottawa Hospital (TOH) have joined in a landmark collaboration to enhance patient care. The two organizations will work together to standardize and improve the quality of services provided by TOH, using the latest advancements in artificial intelligence and smart connected devices. Integrating data and reporting will be a key component of this partnership. The hospital can collect and analyze patient data in real-time with cutting-edge technologies. Merck KGaA has taken a step forward in its quest to revolutionize drug delivery with its latest partnership. The German pharmaceutical giant has teamed up with Biocorp to create an advanced version of a Bluetooth-enabled clip-on device that will integrate seamlessly with one of its drug delivery systems. This collaboration is a testament to Biocorp's expertise in this field, as they have already established successful partnerships with several leading pharmaceutical companies, such as Novo Nordisk and Sanofi. Key Questions Answered in Smart Pills Technology Market Report
Which region's investment opportunities are expected to yield high returns for market participants? What is the market's projected growth rate, and how much is the market valued? Who are the current market leaders, and what are their revenue figures? What are the upcoming global events and trends expected to impact the market? Related Reports in SkyQuest’s Library:

Smart Pills Technology Market is Projected Surpass USD 3077.22 Million by 2028 by growing at a CAGR of 22% from 2022-2028; Rising Demand for Minimally Invasive Devices for Accurate Therapeutic Treatment Propels Market Growth

December 21, 2022 11:19 AM Eastern Standard Time
The Canadian medical aesthetic devices market is expected to register growth at a significant CAGR during the forecast period. The market growth can be attributed to the rising demand for minimally invasive or non-invasive medical devices for diagnosis and making surgical interventions. Besides, increasing technological developments in the healthcare industry are anticipated to fuel the Canada medical aesthetic devices market in the coming years. Medical aesthetic devices are medical tools and equipment used to treat patients' impairments in order to improve their aesthetic appearances. Skin treatment, facial upliftment, excessive fat removal, removal of unwanted facial hairs, scars, moles, and other aesthetic treatments necessitate the use of medical aesthetic devices. The increase in demand for medical procedures to perform aesthetic surgeries such as face lifts and fat removal is driving the growth of the Canada medical aesthetic devices market over the next five years. Furthermore, rising consumer interest in such aesthetic treatments due to changing beauty standards is fueling the adoption of medical aesthetic devices. Rising inclination of the young population toward social acceptability and concerns about their appearance is supporting the growth of the Canada medical aesthetic devices market in the next five years. The increasing penetration of the internet and social media is influencing the local beauty trends. These fashion trends have a strong influence on the younger generation. Furthermore, growing sensitivity toward being accepted on social platforms based on their fashion sense and latest beauty standards is further substantiating the growth of the Canada medical aesthetic devices market in the forecast years until 2027. With the advancement of technology, the healthcare industry in Canada is thriving. Increased government and private investment have supported consistent research and technological advances over the last five years. Multiple market players are actively investing in innovative product development, which is anticipated support the growth of the Canadian medical aesthetic devices market over the next five years. Increasing demand for minimally invasive devices is further driving the growth of the Canada medical aesthetic device market in the upcoming five years. Consumers are demanding such advanced devices to avoid scarring or post-operative fixatures. Technological advancements to introduce laser and light-based treatments are some of its major examples. The Canada medical aesthetic devices market is segmented on the basis of type of devices, application, end user, competitional landscape, and regional distribution. Based on type of devices, the market is further fragmented into energy-based aesthetic device and non-energy-based aesthetic device. Energy-based aesthetic devices are anticipated to register the highest growth in the market during the forecast period. Objective of the Study:
To analyze the historical growth in the market size of the Canada medical aesthetic devices from 2017 to 2021. To estimate and forecast the market size of Canada medical aesthetic devices market from 2023 to 2027 and growth rate until 2027. To classify and forecast the Canada medical aesthetic devices market based on type of device, application, end user, region, and company. To identify the dominant region or segment in the Canada medical aesthetic devices market. To identify drivers and challenges for the Canada medical aesthetic devices market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Canada medical aesthetic devices market. To identify and analyze the profiles of leading players operating in the Canada medical aesthetic devices market. To identify key sustainable strategies adopted by market players in Canada medical aesthetic devices market. Key Target Audience:
Government bodies such as regulating authorities and policy makers
Organizations, forums, and alliances
Report Scope:
In this report, Canada medical aesthetic devices market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Canada Medical Aesthetic Devices Market, By Type of Device:
Energy-Based Aesthetic Device
Skin Resurfacing and Tightening
Hair Removal
Hospitals & Clinics
Ontario region

Canada Medical Aesthetic Devices Market Report 2022: Demand for Minimally Invasive Devices Fuels Growth - ResearchAndMarkets.com

Mitsubishi (TYO: 8058) is a Japanese multinational conglomerate. It is engaged in a wide range of businesses, including energy, metals, machinery, chemicals, consumer goods, and more. It is a major producer and trader of iron ore, copper, construction equipment, power generation equipment, plastics, fertilizers, and more. It was founded in 1954 and is based in Tokyo, Japan.

Mitsubishi

Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement

FloShield

NanoStatics

Acq - Fin

Line of Credit

FloShield is a family of products that improve visualization during laparoscopic surgery. It was founded in 2009 and is based in Cupertino, California.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Interlace Medical vs FloShield

Customers evaluate the quality of Interlace Medical's products using the following success metrics.